The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Valued at $50 billion, the Indian pharmaceutical sector continues to grow, fueled by cost efficiency, cutting-edge ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, ...

ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by ...

Nomura has a Buy rating on Cipla after the company's MD reassured that the competitiveness of the Indian generics biz won't ...

Kenneth Andrade is known for taking high-conviction calls, backing them with sizeable allocation in his portfolio. So where ...

The Ireland-headquartered Felix Pharmaceuticals, which is eyeing a valuation of around $200-250 million for the controlling ...

In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics ...

The differences between the generics industry and other pharma companies wouldn’t exist without patents – legal titles that exclude others from producing or using an invention or innovation ...

arguing that four out of 10 products covered by the scheme are actually branded generics or biosimilars, but was prevented from doing so by a High Court ruling. Samuels said today that the BGMA ...

An Editorial Opinion of The Demopolis Times It seems like there is a battle brewing in the state legislature about whether to ...